Two years of additional market exclusivity for Searie's nonsteroidal anti-inflammatory drug DayPro (oxaprozin) would be provided under legislation introduced Nov. 19 in the Senate (S 1734) by Sens. Simon (D-Ill.), Hatch (R-Utah) and Moseley-Braun (D-Ill.) and in the House (HR 3552) by Rep. Collins (D-Ill.). Searle is based in Chicago. The additional exclusivity for the off-patent drug is being sought to compensate for the time that elapsed between Searle's NDA submission Aug. 10, 1982 and approval of DayPro Oct. 29, 1992.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth